Press Release

    Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration

    October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.

    VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.

    For more information about VARUBI, please access:
    https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html

    Top resources

    View all resources
    a photo that says "2024" with pictures of allies in the background

    Five moments that mattered in 2024

    This year was the Alliance’s 25th year of impact, and we’re looking back on some of the milestones that made 2024 a year to remember.

    Last updated
    The Real Full Monty

    The Real Full Monty Strips Down

    Inspired by the beloved, award-winning 1997 film, The Real Full Monty is an all-new two-hour special in which a daring group of male celebrities will volunteer to bare all to raise awareness for prostate, testicular and colorectal cancer testing and research.

    Last updated